Synthesis, characterization, and evaluation of a novel bifunctional chelating agent for the lead isotopes 203Pb and 212Pb.

[1]  L. Chappell,et al.  Spectrophotometric method for determination of bifunctional macrocyclic ligands in macrocyclic ligand-protein conjugates. , 1999, Nuclear medicine and biology.

[2]  C. Meares,et al.  Total solid-phase synthesis of 1,4,7,10-tetraazacyclododecane-N,N', N'',N'''-tetraacetic acid-functionalized peptides for radioimmunotherapy. , 1999, Bioconjugate chemistry.

[3]  L. Khawli,et al.  Improving monoclonal antibody pharmacokinetics via chemical modification. , 1998, The quarterly journal of nuclear medicine : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology.

[4]  J. Humm,et al.  Radioimmunotherapy with alpha-emitting nuclides , 1998, European Journal of Nuclear Medicine.

[5]  M. Brechbiel,et al.  In vivo evaluation of a lead-labeled monoclonal antibody using the DOTA ligand , 1998, European Journal of Nuclear Medicine.

[6]  G. Henriksen,et al.  ISOLATION OF CYCLOTRON PRODUCED 205BI, 206BI AND 203PB USING A LEAD-SELECTIVE EXTRACTION CHROMATOGRAPHIC RESIN , 1998 .

[7]  J. Stimmel,et al.  Samarium-153 and lutetium-177 chelation properties of selected macrocyclic and acyclic ligands. , 1998, Nuclear medicine and biology.

[8]  J. Shively,et al.  Maleimidocysteineamido-DOTA derivatives: new reagents for radiometal chelate conjugation to antibody sulfhydryl groups undergo pH-dependent cleavage reactions. , 1998, Bioconjugate chemistry.

[9]  T. Waldmann,et al.  Radioimmunotherapy targeting of HER2/neu oncoprotein on ovarian tumor using lead-212-DOTA-AE1. , 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[10]  J. Schlom,et al.  Intraperitoneal radioimmunotherapy of ovarian cancer with 177Lu-CC49: a phase I/II study. , 1997, Gynecologic oncology.

[11]  S. Hassfjell,et al.  212Bi-DOTMP: an alpha particle emitting bone-seeking agent for targeted radiotherapy. , 1997, Nuclear medicine and biology.

[12]  O. Gansow,et al.  The use of 212Pb-labeled monoclonal antibody in the treatment of murine erythroleukemia. , 1996, International journal of radiation oncology, biology, physics.

[13]  S. Srivastava.  Criteria for the selection of radionuclides for targeting nuclear antigens for cancer radioimmunotherapy. , 1996, Cancer biotherapy & radiopharmaceuticals.

[14]  J. Morrow,et al.  Restoration of catalytic activity by replacement of a coordinated amide group: Synthesis and laser-induced luminescence studies of the phosphate diester transesterification catalyst [Eu(NBAC)]{sup 3+} , 1996 .

[15]  M. Brechbiel,et al.  Lead(II) complexes of 1,4,7,10-tetraazacyclododecane-N,N′,N″,N‴-tetraacetate: solution chemistry and application to tumor localization with 203Pb labeled monoclonal antibodies , 1995 .

[16]  Joseph H. Reibenspies,et al.  The Amide Oxygen as a Donor Group. Metal Ion Complexing Properties of Tetra-N-acetamide Substituted Cyclen: A Crystallographic, NMR, Molecular Mechanics, and Thermodynamic Study , 1995 .

[17]  E. Gautherot,et al.  Bifunctional antibodies for radioimmunotherapy. , 1995, Hybridoma.

[18]  G. Meinken,et al.  Development and evaluation of copper-67 and samarium-153 labeled conjugates for tumor radioimmunotherapy , 1995 .

[19]  Melvyn Rowen Churchill,et al.  Lanthanide(III) tetraamide macrocyclic complexes as synthetic ribonucleases: Structure and catalytic properties of [La(tcmc)(CF 3 SO 3 )(EtOH)](CF 3 SO 3 ) 2 , 1994 .

[20]  R. Hancock,et al.  Stability enhancement of heavy-metal–macrocycle complexes via pendant amide coordination , 1994 .

[21]  T. Koike,et al.  Novel bifunctional macrocyclic chelating agents appended with a pendant-type carboxymethylamino ligand and nitrobenzyl group and stability of the 88YIII complexes , 1993 .

[22]  S. Mirzadeh,et al.  The Chemical Fate of 212Bi-DOTA Formed by β- Decay of 212Pb(DOTA)2-*** , 1993 .

[23]  M. Brechbiel,et al.  Effective α-Particle-mediated Radioimmunotherapy of Murine Leukemia , 1992 .

[24]  M. Brechbiel,et al.  Convenient synthesis of bifunctional tetraaza macrocycles. , 1992, Bioconjugate chemistry.

[25]  C.‐C. Wu,et al.  Radiolabeling of monoclonal antibodies with metal chelates , 1991 .

[26]  S. Mirzadeh,et al.  Improved in vivo stability and tumor targeting of bismuth-labeled antibody. , 1990, Cancer research.

[27]  D. Parker.  Tumour targeting with radiolabelled macrocycle–antibody conjugates , 1990 .

[28]  J. P. Cox,et al.  Synthesis of a kinetically stable yttrium-90 labelled macrocycle–antibody conjugate , 1989 .

[29]  Krishan Kumar,et al.  Lead(II) and bismuth(III) complexes of the polyazacycloalkane-N-acetic acids nota, dota, and teta , 1989 .

[30]  M. Kuroki,et al.  Generation and characterization of B72.3 second generation monoclonal antibodies reactive with the tumor-associated glycoprotein 72 antigen. , 1988, Cancer research.

[31]  J. Schlom,et al.  Radioimmunolocalization of human carcinoma xenografts with B72.3 second generation monoclonal antibodies. , 1988, Cancer research.

[32]  S. Denardo,et al.  The peptide way to macrocyclic bifunctional chelating agents: synthesis of 2-(p-nitrobenzyl)-1,4,7,10-tetraazacyclododecane-N,N',N",N'''-tetraacetic acid and study of its yttrium(III) complex. , 1988, Journal of the American Chemical Society.

[33]  S. Larson,et al.  Complementation of intracavitary and intravenous administration of a monoclonal antibody (B72.3) in patients with carcinoma. , 1987, Cancer research.

[34]  P. Fraker,et al.  Protein and cell membrane iodinations with a sparingly soluble chloroamide, 1,3,4,6-tetrachloro-3a,6a-diphrenylglycoluril. , 1978, Biochemical and biophysical research communications.

[35]  P. Hammond.  The effects of chelating agents on the tissue distribution and excretion of lead. , 1971, Toxicology and applied pharmacology.

[36]  F. Weigel.  BURRIS BELL CUNNINGHAM , 1971 .

[37]  U. K. Laemmli,et al.  Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4 , 1970, Nature.

[38]  O. H. Lowry,et al.  Protein measurement with the Folin phenol reagent. , 1951, The Journal of biological chemistry.